No Data
Leerink Partners Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Announces Target Price $5
Leerink Partners analyst Roanna Ruiz maintains $Xeris Pharmaceuticals(XERS.US)$ with a buy rating, and sets the target price at $5.According to TipRanks data, the analyst has a success rate of 32.4%
Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating
Craig-Hallum analyst Chase Knickerbocker maintains $Xeris Pharmaceuticals(XERS.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 44.8% and a total average return of
Xeris Pharmaceuticals (XERS) Gets a Buy From Craig-Hallum
Xeris Pharmaceuticals Undergoes Executive Leadership Transition
Xeris Biopharma CEO Paul Edick to Retire
Express News | Xeris Biopharma Reports Preliminary Q2 Total Revenue To Exceed $47M, Representing Over 23% Growth Over Last Year; Estimate $44.894M